Healthcare - Biotechnology - NASDAQ - US
$ 33.215
0.651 %
$ 1.89 B
Market Cap
15.74
P/E
CASH FLOW STATEMENT
219 M
OPERATING CASH FLOW
-46.4 M
INVESTING CASH FLOW
-106 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Harmony Biosciences Holdings, Inc.
| Net Income | 129 M |
| Depreciation & Amortization | 24.4 M |
| Capital Expenditures | -312 K |
| Stock-Based Compensation | 31.7 M |
| Change in Working Capital | 35 M |
| Others | 59.4 M |
| Free Cash Flow | 219 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | 128.9 | 181.5 | 34.6 | (36.9) | (152.0) | (39.9) |
| Depreciation & Amortization | 24.4 | 23.4 | 18.8 | 10.2 | 3.2 | 0.2 |
| Deferred Income Tax | (13.4) | (85.9) | 26.1 | 25.7 | 0 | 0 |
| Stock Based Compensation | 31.7 | 26.2 | 15.7 | 4.7 | 9.9 | 1.1 |
| Other Operating Activities | 12.9 | 3.5 | 2.7 | 4.9 | 55.1 | 2.1 |
| Change in Working Capital | 35.0 | (4.1) | 0.6 | (11.6) | 8.3 | (0.2) |
| Cash From Operations | 219.4 | 144.5 | 98.6 | (3.0) | (75.4) | (38.8) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | (0.3) | (40.2) | (100.3) | (2.0) | (127.1) | (1.3) |
| Other Items | (46.1) | (101.7) | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | (46.4) | (141.8) | (100.3) | (2.0) | (127.1) | (1.3) |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | (100.0) | 0 | 0 | (0.2) | (1.1) | (3.2) |
| Total Debt Repaid | (1.2) | (2.0) | (0.5) | 79.4 | 100.0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (4.3) | 8.8 | (22.1) | (17.7) | 93.8 | 24.8 |
| Cash From Financing Activities | (105.6) | 6.8 | 7.4 | 209.2 | 143.8 | 21.6 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 67.4 | 9.5 | 5.7 | 204.2 | (58.8) | (18.5) |
| FREE CASH FLOW | ||||||
| Free Cash Flow | 219.1 | 104.3 | (1.7) | (5.0) | (202.6) | (40.1) |